BD named Vitor Roque as chief financial officer Thursday, ending the medtech company’s seven-month search for a permanent replacement for Chris DelOrefice. In October, DelOrefice told BD that he ...
After parting ways with its diabetes franchise nearly three years ago, BD is slimming down even further with a plan to divest its diagnostic and biosciences businesses as the company nears the finish ...
Travis Steed, the medical device analyst at Bank of America. Next up, we have Becton, Dickinson, Tom Polen, CEO; and Vitor Roque, the newly announced CFO. I think you've been to Vegas a couple of ...
BD has become the subject of a lawsuit from Tela Bio, with the rival maker of surgical mesh implants saying the major medtech wielded its sector dominance to push competing products out of the hernia ...
StockStory.org on MSN
BD’s (NYSE:BDX) Q1 CY2026 sales beat estimates
Medical technology company Becton, Dickinson and Company (NYSE:BDX) announced in Q1 CY2026, with sales up 5.2% year on year ...
Medical Device Network on MSN
BD uplifts FY26 revenue outlook based on steady portfolio performance
The uplifted FY26 outlook reflects a reversal on Q1 FY26, in which BD trimmed its outlook due to impacts from the sale of its ...
The scientific-instrument company Waters will deepen its biological sciences footprint by merging with the biosciences and diagnostic solution business of Becton, Dickinson (BD). The companies value ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results